Better Health for All

ClearPoint Neuro's core products, including the ClearPoint system and SmartFlow cannula, are designed for neurological procedures, targeted drug delivery, and treatment of complex neurological disorders such as AADC deficiency, Parkinson's disease, epilepsy, and brain tumors.

These applications deliver revolutionary health benefits, with over 3,500 cases performed and supported. The company has no products with significant negative health impacts. The company deploys significant resources to develop foundational capabilities for MRI-guided interventions, build an intellectual property portfolio, and identify and build out commercial applications for its technologies. However, the percentage of the R&D budget allocated to health improvement is not specified. The company is subject to various laws protecting the confidentiality and security of personal information and uses reasonable administrative, physical, and technical safeguards, but acknowledges that security measures cannot guarantee prevention of unauthorized access. The company's force majeure clause includes pandemics, epidemics, and viral outbreaks, indicating a structured crisis response. Clinical trials must be conducted in compliance with federal regulations and good clinical practice, and the SmartFlow cannula is being used in partnership or evaluation with more than 20 biologics and drug delivery companies in various stages of trials. The company provides industry-relevant compliance training to new employees and requires customers to complete training for product use, which contributes to healthcare education.

Fair Money & Economic Opportunity

ClearPoint Neuro, Inc. is a medical device company, and its core business activities do not involve lending, insuring, moving, or storing money for consumers. The company does not offer consumer credit products, manage customer financial data, or engage in financial services that would directly impact consumer credit scores, savings, or debt burdens. While the company provides patient education webinars

and makes scientific manuscripts open access, these initiatives are related to health and medical information, not financial literacy or data accessibility as defined by the rubric for financial institutions. Therefore, all KPIs related to fair money and economic opportunity are not applicable to ClearPoint Neuro, Inc.

Fair Pay & Worker Respect

ClearPoint Neuro Inc. has no specific regulatory actions, violations, fines, or compliance issues mentioned across the provided articles.

Multiple articles explicitly state no information on these topics or provide empty arrays for regulatory actions or violations.

Kind to Animals

ClearPoint Neuro, Inc. engages in animal testing.

However, the provided information does not offer further details regarding the extent of animal testing, specific policies, or reduction goals. No data is available on cruelty-free certifications, alternative testing methods, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, R&D investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.

No War, No Weapons

ClearPoint Neuro Inc. is described as a medical device company focused on neurosurgery technology.

Multiple articles explicitly state that the company is not in the defense industry and that the provided information does not contain data relevant to defense or weapons. This indicates that the company has no revenue from arms or defense contracts and does not develop or sell dual-use products with military applications.

Safe & Smart Tech

ClearPoint Neuro experienced a data breach affecting 92,845 patients, with unauthorized access detected around May 29, 2025, and notifications mailed on November 21, 2025.

Following the breach, affected systems were wiped and rebuilt, and additional security measures were implemented, with data security policies and network security software under review. No misuse of the compromised data has been identified. The company states it does not rent or sell personal information. ClearPoint Neuro reported the data breach to the HHS Office for Civil Rights and is FDA-registered, certified to ISO 13485, and the Medical Device Single Audit Program (MDSAP). It also received European Medical Device Regulation (EU MDR) clearance for some products. The privacy policy, last updated January 1, 2026, outlines the collection of personal and aggregate information, use of cookies, and Google Analytics. It mentions user rights for EEA, Switzerland, and UK visitors, including access, correction, restriction, or deletion of personal data, and the right to lodge a complaint with a supervisory authority. The company uses reasonable administrative, physical, and technical safeguards to secure personal information, but does not explicitly detail encryption implementation or specific authentication methods. Data is retained for a reasonable period after it is no longer needed, with archiving prior to final deletion. The Audit Committee oversees cybersecurity risks, and a Cybersecurity Steering Committee has been formed, which conducts penetration testing, phishing training, and continuous security event monitoring. The company has adopted an incident response plan and, to date, has not experienced a cyber-attack with a material adverse impact.

Zero Waste & Sustainable Products

The company reported no waste disposal violations.

No specific information was available regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management practices, product durability, repairability scores, waste audit frequency, zero waste certifications, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.